

Twist Bioscience launches IVDR-compliant precision Dx portfolio for whole exome sequencing

March 7, 2024 | News

Unleashing Precision in Clinical Genomics capacity with Precision Dx workflow enabling consistent yield from high-complexity libraries



Twist Bioscience Corporation, a leading expert in high-quality synthetic DNA using its silicon platform, has launched Twist Precision Dx next-generation sequencing (NGS) Products in compliance with European Union (EU) in vitro diagnostic regulations (IVDR).

With Precision Dx, over 98% of target bases can be covered at 30x and uniform enrichment results can be achieved with consistent yields. Precision Dx Products are intended for use with high-quality genomic DNA derived from human cells and provide workflow flexibility.

The Precision Dx products are designed to enable panel sequencing within a clinical setting. The 3 CE-marked portfolios include

- The Twist Precision Prep and Enrichment Dx Kit (Reagents for enzymatic fragmentation, library preparation, and target enrichment), which is panel-agnostic
- The Twist Precision Exome Dx Panel (Targeted capture probes for exome enrichment)
- Twist Precision Exome Dx Kit (Reagents for enzymatic fragmentation, library preparation, and target enrichment along with targeted capture probes for exome enrichment; IVDR compliant workflow)

Furthermore, Twist is collaborating with Platomics to enable laboratories to efficiently generate documentation on Platomics' multi-stakeholder platform for workflows incorporating the Twist Precision Exome Dx Kit, and to help automate regulatory processes and accelerate compliance for laboratories and manufacturers.